Novartis Czech Republic's net debt stood at CZK 51.2 mil and accounted for 7.85% of equity at the end of 2017. The ratio is up 4.76 pp compared to the previous year.
Historically, the firm’s net debt to equity reached a high of 494% in 2002 and a low of -183% in 2004 between 2000 and 2017. The average for the last five years was 6.25%.
Net debt to EBITDA was calculated at 0.371x at the end of the year. That is up from 0.696x seen in 2012. The ratio reached a high of 12.8x in 2004 and a low of -38.0x in 2007.
The company’s cost of funding amounted to 15.6% in 2017, down which is above the 5-year of 27.6%. Funding costs have “eaten” some 4.96% of the operating profit generated in 2019.
You can see all the company’s data at Novartis Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
